IMVT · Immunovant, Inc.

The thesis

Immunovant's remaining case rests on IMVT-1402 (imeroprubart) in rheumatoid arthritis, Graves' disease and myasthenia gravis, and the shares closed at $28.88 on 27 October 2026, 35.8% below the 52-week high of $44.96. The fiscal second-quarter report on 9 November 2026 updates timelines and cash, and the rheumatoid arthritis topline guided for the second half of 2026 settles whether the platform case survives.

Two events drove the decline. Immunovant's cutaneous lupus trial failed its primary endpoint on 23 September 2026. On 8 October 2026, argenx said an independent data monitoring committee recommended stopping its Phase 3 UNITY study of subcutaneous efgartigimod in Sjögren's disease for futility, according to Fierce Pharma.

The call stays at low conviction: the shares are more likely to lag than lead the S&P 500 over the next three months. Adjusted daily closes show $27.90 on 14 October 2026 and $28.88 on 27 October 2026, so the shares have steadied just above the $25 invalidation level. Nothing new on the pipeline has been reported since the 14 October 2026 note.

The narrative is maturing: the story is well known, and the shares trade on class-wide doubt about whether lowering immunoglobulin G converts into clinical benefit in new diseases. Immunovant's three-month price change is -26.8% and its 14-day relative strength index (a 0–100 momentum gauge) is 34.4, both from adjusted daily closes on 27 October 2026.

Bullish and bearish views on Immunovant, Inc.

The bull case on Immunovant, Inc. (IMVT), in brief: Other programmes are unchanged. The bear case: First controlled test of IMVT-1402 failed.

Bull case

• Other programmes are unchanged. Immunovant's 23 September 2026 release says all other clinical development timelines remain on track. Potentially registrational Graves' disease and myasthenia gravis data are guided for 2027.
• Argenx failed with a different drug. The UNITY futility finding concerns efgartigimod, a different molecule from IMVT-1402. Immunovant said on 23 September 2026 that its own Sjögren's timeline remains on track.
• Rheumatoid arthritis data already positive. On 20 May 2026 the company reported a 54.5% ACR50 response rate at Week 16 in the open-label portion of its difficult-to-treat rheumatoid arthritis trial. ACR50 is the American College of Rheumatology's measure of 50% improvement. Open-label means there was no placebo comparison.
• Cash funds the 2027 readouts. Immunovant reported $797.8 million in cash and equivalents at 30 June 2026. Management's 6 August 2026 statement described runway to a potential Graves' disease launch.

Bear case

• First controlled test of IMVT-1402 failed. The cutaneous lupus study enrolled 57 adults and missed its Week 12 primary endpoint on 23 September 2026. The earlier batoclimab setback in thyroid eye disease raised the same question about whether lowering immunoglobulin G converts into benefit.
• A class peer has now failed too. Argenx stopped UNITY for futility on 8 October 2026, and Benzinga reported Immunovant fell 4.8% to $30.50 in pre-market trading that day.
• No numbers on the lupus gap. The topline release gave no CLASI-A values, so the size of the gap to placebo is not public.
• Losses continue. Immunovant reported a net loss of $153.2 million for the quarter ended 30 June 2026. Benzinga reported fiscal first-quarter EPS of -$0.75 against a -$0.61 estimate on 6 August 2026.

Price setup

The adjusted close on 27 October 2026 was $28.88, against a 52-week high of $44.96. The close on 14 October 2026 was $27.90, so the shares have recovered part of the post-Sjögren's drop without reclaiming the $30.50 pre-market level of 8 October 2026.

The relative strength index rose from 9.5 on 14 October 2026 to 34.4 on 27 October 2026, which moves it out of the extreme sell-off reading. The three-month change of -26.8% shows the shares remain well below their level in late July.

Crowding evidence is limited. Immunovant announced on 21 October 2026 that it will report results on 9 November 2026, so an earnings date is now close. No insider sales or share issuance are reported in recent filings.

Catalysts, next 30 days

• 9 November 2026: fiscal second-quarter results and business update. Immunovant announced the date in its 21 October 2026 release. The report covers the quarter ended 30 September 2026 and updates cash against the $153.2 million loss of the prior quarter.
• Same report: timeline confirmation. Management either reaffirms or re-dates the rheumatoid arthritis, Graves' disease and myasthenia gravis disclosures.
• 31 December 2026: end of the guided window for the rheumatoid arthritis topline. This falls outside the 30 days but carries the case.
• 2027 (guided): Graves' disease and myasthenia gravis toplines. These carry most of the asset's value now that cutaneous lupus is dropped.

What would change the view

The case breaks if the rheumatoid arthritis topline fails to separate from placebo on its prespecified primary endpoint, or if the topline slips into 2027. A fiscal second-quarter report on 9 November 2026 that drops another indication would also narrow the pipeline to the two 2027 readouts.

On price, a daily close below $25 would extend the post-lupus-failure decline and end the case. A second controlled failure for any IgG-lowering drug in an autoimmune disease would deepen the class-wide doubt.

A rheumatoid arthritis result with clear placebo separation, with timelines reaffirmed on 9 November 2026, would move the read toward the bull case.

What it trades with

Roivant Sciences is Immunovant's majority shareholder, and its shares moved with Immunovant on the 8 October 2026 news. Argenx is the closest read-across: its 8 October 2026 futility finding pulled Immunovant down 4.8% in pre-market trading. Further data from efgartigimod or other neonatal Fc receptor blockers (drugs that lower immunoglobulin G) in new diseases would likely move Immunovant in the same direction.